Postby boxhill » Fri Mar 08, 2019 9:58 am
Pyro, Keytruda is FDA approved for any cancer that is MSI-H, including CRC. My insurance covers it. Right now, there is a big push in CRC oncology to see if they can extend the benefits of immunotherapy to people who are MSS, especially since that represents the vast majority of patients. They are looking at whether it will help MSS people who have a higher genetic mutation burden in their tumor. (To put this in perspective, I am MSI-H, and my mutation level is something like 56. I'm in the top 4% or so. They are trying Keytruda with MSS tumors that are around level 12, which is high for MSS.)
Looking at your treatment, I am guessing that you are KRAS wildtype, since you've had the drugs that go with that.
If you would add your genetic info to your sig, it would help people understand your situation and make more useful comments.
Good luck getting the keytruda, and I hope it helps you. I believe there is also research being done around whether using two immunotherapies instead of a single agent will improve its efficacy for more patients. (Opdivo+Yervoy being a prominent example already in use.)
https://www.curetoday.com/articles/drug ... tal-cancer
Last edited by
boxhill on Fri Mar 08, 2019 11:19 am, edited 1 time in total.
F, 64 at DX CRC Stage IV
3/17/18 blockage, r hemi
11 of 25 LN,5 mesentery nodes
5mm liver met
pT3 pN2b pM1
BRAF wild, KRAS G12D
dMMR, MSI-H
5/18 FOLFOX
7/18 and 11/18 CT NED
12/18 MRI 5mm liver mass, 2 LNs in porta hepatis
12/31/18 Keytruda
6/19 Multiphasic CT LNs normal, Liver stable
6/28/19 Pause Key, predisone for joint pain
7/31/19 Restart Key
9/19 CT stable
Pain: all fails but Celebrex
12/23/19 CT stable
5/20 MRI stable/NED
6/20 Stop Key
All MRIs NED